IMC-A12: Phase I started

ImClone began an open-label, U.S. Phase I trial (2007-0595) in about 40 patients with advanced solid tumors and lymphoma to evaluate IMC-A12 plus Torisel temsirolimus. Patients will receive 20 mg/wee...